CURRENT ISSUE
EDITOR'S PICKS
Review Series on indolent myelodysplasia
Introduction to the Review Series on Myelodysplasia
Pathogenesis and inflammaging in myelodysplastic syndrome
Diagnosis of myelodysplastic syndromes: the classic and the novel
Genome sequencing in the management of myelodysplastic syndromes and related disorders
Treatment of lower-risk myelodysplastic syndromes
Treatment of high-risk myelodysplastic syndromes
ARTICLES IN THREE SENTENCES
Article
CODOX-M/IVAC-R versus DA-EPOCH-R in double-hit/triplehit lymphoma patients aged 60 years or under
There is no standardized treatment for patients with double-hit lymphoma (DHL) and triple-hit lymphoma (THL). Atallah-Yunes and colleagues present results of a retrospective analysis to investigate outcome differences between patients with DHL/THL aged 60 years or younger treated with CODOX-M/IVAC-R or DA-EPOCH-R. They found no difference in overall survival between the two groups; however, the CODOX-M/IVAC-R group had improved event-free survival, a higher complete response rate and no increase in treatment-related mortality compared to the DA-EPOCH-R group.
Letter
Unraveling the germline inheritance of the JAK2F556V gene mutation in familial thrombocythemia: a comprehensive analysis of 11 family members and potential implications for surveillance
Familial thrombocythemia is an ultra-rare inherited syndrome that is characterized by elevated platelet counts (>450x109/L). While the JAK2 V617F mutation has been extensively studied in the context of sporadic myeloproliferative neoplasms (MPN), understanding of germline JAK2 mutations is less advanced. Meggendorfer and colleagues present JAK2 F556V, a new germline JAK2 mutation, in a large family with thrombocythemia.
Letter
Safety and efficacy of human amniotic epithelial stem cell eye drops in ocular chronic graft-versus-host disease
Ocular chronic graft-versus-host disease (cGvHD) is present in more than 50% of patients with cGvHD; however, current clinical therapies provide only limited benefit. Cheng and colleagues conducted a trial in patients with ocular cGvHD using human amniotic epithelial stem cells (hAESC). They demonstrated that hAESC eye drops are a safe, non-invasive, and efficient therapy for patients with ocular cGvHD.
Letter
BET inhibitors downregulate the expression of the essential lncRNA SMILO in multiple myeloma through regulation of the transcription factor FLI1
Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that bind to acetylated histones in active enhancer and promoter regions, likely with a role in oncogenic enhancers of cancer. Gómez-Echarte and colleagues hypothesized that the use of BET inhibitors (BETi) in multiple myeloma (MM) could contribute to the elimination of abnormal plasma cells. Through RNA-sequencing analysis following 72 hours of treatment of MM-derived cell lines with the BETi JQ1, they demonstrated the potential of BETi to modify gene expression through regulation of de novo active chromatin regions.
TAKE ADVANTAGE FROM HAEMATOLOGICA
